Assessing and Mitigating Cardiovascular Risk in Diabetic Patients: A Comprehensive Review
OthersPage Navigation
Introduction
Cardiovascular disease (CVD) remains a leading cause of morbidity and mortality in diabetic patients. Early detection and risk mitigation are critical.
Assessment of Cardiovascular Risk
Consideration of risk factors such as hypertension, dyslipidemia, and smoking status is essential in assessing CVD risk in diabetics.
Risk Mitigation Strategies
Management strategies include lifestyle modifications, pharmacological interventions, and regular monitoring to reduce CVD risk.
Conclusion
Effective assessment and mitigation of cardiovascular risk in diabetic patients can significantly reduce CVD-related morbidity and mortality.
Recommended News For You
Recommended Articles For You
Featured News
Featured Articles
Featured Events
Featured KOL Videos
1.
Immunotherapy and targeted radiation shrink liver tumors, enabling surgery
2.
Proton Therapy Fails to Beat IMRT in Prostate Cancer
3.
Advancing Care in ES-SCLC: Personalized Strategies, New Therapies, and Real-World Insights
4.
Detecting pancreatic cancer through changes in body composition and metabolism
5.
In a clinical trial, "3D mammography" nearly reduces the incidence of breast cancer between two screening exams.
1.
Cancer Memory: A Persistent Threat to Tumor Recurrence and Metastasis
2.
The Benefits and Risks of Cervical Conization
3.
Unveiling the Hidden Causes of Anemia: A Comprehensive Look at a Common Condition
4.
Critical Care Updates on Hematopoietic Dysfunction During Prolonged Critical Illness
5.
Unlocking a New Era in Bladder Cancer Treatment: A Review of the TAR-200 Intravesical Drug Delivery System
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Managing Fatigue During Cancer Treatment
2.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part II
3.
A New Era in Managing Cancer-Associated Thrombosis
4.
The Reign of the CROWN Trial and the Dawn of a New Era in Frontline Management- Further Discussion
5.
ESMO Breast Cancer 2022: P Reality X- A Restrospective Analysis
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Welcome to Hidoc Dr.
Join to enhance your clinical skills and gain specialized in-depth medical knowledge